Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RORB | Q92753 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642060 | 0.93 | MAPK14 (0.59) | MAPK14KDM4EPOLBMAPK13MAPK12 | |
| SCHEMBL1642094 | 0.91 | MAPK14 (0.47) | MAPK14KDM4EPOLBRORBHPGD | |
| SCHEMBL1642040 | 0.86 | MAPK14 (0.51) | MAPK14KDM4EPOLBRORBHPGD | |
| SCHEMBL1643526 | 0.85 | RORB (0.51) | MAPK14KDM4EPOLBRORBALDH1A1 | |
| SCHEMBL1644025 | 0.82 | HPGD (0.43) | MAPK14KDM4EPOLBHPGDGRM4 | |
| SCHEMBL1643090 | 0.81 | RORB (0.47) | MAPK14RORBGRM4LMNAMAPK13 | |
| SCHEMBL1643725 | 0.81 | MAPK14 (0.57) | MAPK14KDM4EMAPK13MAPK12MAPK11 | |
| SCHEMBL1642331 | 0.80 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1644182 | 0.79 | ALDH1A1 (0.49) | MAPK14RORBALDH1A1LMNAGAA | |
| SCHEMBL1643812 | 0.79 | MAPK14 (0.48) | MAPK14HPGDMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-04-28 | — | — | US | claimed |
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-04-28 | — | — | US | disclosed |
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | disclosed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | disclosed |
| EP-2049537-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2009-04-22 | — | — | EP | disclosed |
| EP-1987005-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008017461-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007096072-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | MAPK1, MAP4K2, MAPK3 | MAPK14 33/4885KDM4E 2470/4885POLB 1840/4885 |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | MAPK1, MAPK7, MAPKAPK2 | MAPK14 23/4885KDM4E 4589/4885POLB 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.